[12].AHA 2024. Exploring Provider Hesitancy in Prescribing SGLT2 Inhibitor for Acute Heart Failure Patients: Insights from a Single-Center Teaching Hospital Survey. AHA 2024. [13].John J V McMurray, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Me...
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in pati
另一方面,SGLT2i 肾脏排糖效果通常取决于血浆中未结合的药物对 SGLT2 的抑制率和作用时间,因此,如果药物要达到高效降糖效果,更高的 SGLT2 抑制率、更长的 SGLT2 作用时间是必要条件[7]。IC50 的数值体现的是达到 50% 抑制作用所需的浓度[17],达格列净和艾托格列净数值表现更优,意味着两款药物可以在更低的...
There is currently minimal information regarding risk factors for the development of sodium-glucose cotransporter-2 inhibitor (SGLT2i)-related diabetic ketoacidosis (DKA). We aim to identify individual patient characteristics associated with cases of SGLT2i-related DKA to better describe potential risk ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to prevent the progression of diabetic kidney disease (DKD). However, their impact on ren
Study Cohort and Patient Characteristics A total of 417,304 patients met study inclusion and exclusion criteria for the SGLT2 inhibitor versus DPP-4 inhibitor cohort (74,161 SGLT2 inhibitor initiators and 343,143 DPP-4 inhibitor initiators), and 211,235 met inclusion and exclusion criteria for...
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809-813. doi:10.1038/s41591-022-01703-8PubMedGoogle ScholarCrossref 30. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2...
This study aimed to quantify the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on N-terminal pro-B-type natriuretic peptide (NT-proBNP) as
Question: When Should a Patient Taking a RAS Inhibitor for the Treatment of CKD Initiate an SGLT2 Inhibitor? Question: How Concerned Should I Be About an Initial eGFR Decline When Initiating SGLT2 Inhibitor Therapy? Question: Should Patients at Lower Risk of Progression Still Initiate an SGLT2 ...
Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approve